Tempus AI stock crashed Tuesday as investors questioned the medical AI company's long-term growth prospects. But William Blair analyst Andrew Brackmann remains a believer in the stock. Tempus uses ...

Tempus AI TEM and Doximity DOCS stand out as emerging players in the AI health tech space. These two offer distinct approaches to innovation and market disruption. Tempus AI is focused on ...

The Chicago-based startup formed in 2020 by Tempus AI executives Ryan Fukushima and Eric Lefkofsky is using an artificial intelligence platform, PathOS, to develop drugs, primarily in the oncology ...

When it comes to shares of Tempus AI (NASDAQ: TEM), many may feel like they're standing on a dock watching the stock sail off to the horizon. It's understandable if you identify with this.